Abstract: Embodiments provided herein relate to methods and compositions for next generation sequencing. Some embodiments include the preparation of a template library from a target nucleic acid using one-sided transposition, sequencing the template library, and capturing the contiguity information.

Abstract: The present invention provides engineered glycosyltransferase (GT) enzymes, polypeptides having GT activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention provides engineered sucrose synthase (SuS) enzymes, polypeptides having SuS activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention also provides compositions comprising the GT enzymes and methods of using the engineered GT enzymes to make products with ?-glucose linkages. The present invention further provides compositions and methods for the production of rebaudiosides (e.g., rebaudioside M, rebaudioside A, rebaudioside I, and rebaudioside D). The present invention also provides compositions comprising the SuS enzymes and methods of using them. Methods for producing GT and SuS enzymes are also provided.

Abstract: The present invention relates to a process wherein one or more dye precursors, e.g., indole, are provided to a textile and converted by one or more enzymes, e.g., an oxidizing enzyme, to provide the textile with a dye, e.g. indigo. At least the oxidizing enzyme is a hybrid enzyme including a binding domain that is suitable to bind the enzyme to the textile and/or increase the affinity of the enzyme for the textile, in particular, a cellulose binding domain (CBD).

Abstract: The present invention relates to the use of type III polyketide synthases of bacteria, such as actinomycete bacteria, as phloroglucinol synthases. The present invention also relates to the isolated nucleic acid molecules encoding these type III polyketide synthases, and also to the vectors and the host cells comprising such nucleic acid molecules. The present invention also relates to methods for producing phloroglucinol.

Abstract: The present disclosure provides a method for detecting L-serine based on cysteine desulfurase-containing living Escherichia coli cells, and belongs to the technical field of amino acid detection. The method includes the following steps: incubating an unknown sample with the cysteine desulfurase-containing living E. coli cells to produce a red substance, and qualitatively or semi-quantitatively detecting L-serine content in the unknown sample according to color changes of the red substance of the living E. coli cells, or quantitatively detecting L-serine content in the unknown sample by measuring absorbance of a lysate of the living E. coli cells. The detection method provided by the present disclosure is simple and convenient in process, few in reaction steps and stable in enzymatic activity of living cells.

Abstract: Provided herein is a method of using transposition to improve methods of sequencing RNA molecules. Provided herein is a method of tagging nucleic acid duplexes, such as DNA:RNA duplexes or DNA:DNA duplexes. The method includes the steps of providing a transposase and a transposon composition, providing one or more nucleic acid duplexes immobilized on a support, and contacting the transposase and transposon composition with the one or more nucleic acid duplexes under conditions wherein the one or more nucleic acid duplexes and transposon composition undergo a transposition reaction to produce one or more tagged nucleic acid duplexes, wherein the transposon composition comprises a double stranded nucleic acid molecule comprising a transferred strand and a non-transferred strand.

Abstract: The present invention relates to a compound or a pharmaceutical salt thereof comprising a hexapeptide sequence of formula (I), its method of synthesis and its use in anticancer therapy. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.

Abstract: There is described herein a plant cell comprising: (i) a polynucleotide comprising, consisting or consisting essentially of a sequence having at least 95% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 3 or SEQ ID NO: 9 or SEQ ID NO: 11 or SEQ ID NO: 17 or SEQ ID NO: 19 or SEQ ID NO: 21 or SEQ ID NO: 23; or a polynucleotide comprising, consisting or consisting essentially of a sequence having at least 80% sequence identity to SEQ ID NO: 5 or SEQ ID NO: 7 or SEQ ID NO: 13 or SEQ ID NO: 15; (ii) a polypeptide encoded by the polynucleotide set forth in (i); (iii) a polypeptide comprising, consisting or consisting essentially of a sequence having at least 94% sequence identity to SEQ ID NO: 2; or at least 93% sequence identity to SEQ ID NO: 4; or least 95% sequence identity to SEQ ID NO: 6; or at least 96% sequence identity to SEQ ID NO: 8; or at least 93% sequence identity to SEQ ID NO: 10 or SEQ ID NO: 12; or at least 95% sequence identity to SEQ ID NO: 14; or at least 96% sequence identity to SEQ ID NO: 16; o

Abstract: Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3? heterodimerization or CDC25A binding to 14-3-3?. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Trp-Tyr-Trp-Lys-NH2 (SEQ ID NO: 1), a second targeting peptide comprising a structure of phospho-Ser178; Ac-Thr-Gln-Arg-Gln-Asn-Ser-(PO32?)-Ala-Pro-Arg-Met-Leu-Ser-Ser-Asn-NH2 (SEQ ID NO: 2), and a third targeting peptide comprising a structure of phospho-Thr507 residue; Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO32?)-Trp-Ala-Gly-Glu-Lys-Ser-Lys-Arg-NH2 (SEQ ID NO: 3).

Abstract: The present invention provides engineered polypeptides that are useful for the asymmetric synthesis of ?-hydroxy-?-amino acids under industrial-relevant conditions. The engineered polypeptides disclosed in this invention were developed through directed evolution based on the ability of catalytic synthesis of (2S, 3R)-2-amino-3-hydroxy-3-(4-nitrophenyl) propanoic acid. The present disclosure also provides polynucleotides encoding engineered polypeptides, host cells capable of expressing engineered polypeptides, and methods of producing ?-hydroxy-?-amino acids using engineered polypeptides. Compared to other processes of preparation, the use of the engineered polypeptides of the present invention for the preparation of ?-hydroxy-?-amino acids results in high purity of the desired stereoisomers, mild reaction conditions, low pollution and low energy consumption. So, it has good industrial application prospects.

Abstract: The present disclosure relates to a construction method of a Mucor circinelloides cell factory for producing dihomo-?-linolenic acid and a fermentation technology, belonging to the field of genetic engineering. In the present disclosure, ?-linolenic acid elongase gene glelo is obtained from Mortierella alpine by cloning, the gene is ligated to an integrative plasmid pMAT1552, and transformed into a Mucor circinelloides defective strain Mu402, and the gene glelo is integrated into Mucor circinelloides genome through homologous recombination, to obtain the recombinant strain Mc-glelo, and finally, the expression of the gene glelo in Mucor circinelloides is realized. The lipid content in the recombinant strain Mc-glelo is not obviously different from that in the control strain Mc1552, however, the lipid composition changes greatly, and dihomo-?-linolenic acid appears in the lipids of the recombinant strain Mc-glelo, and the content thereof reaches 5.7% of the total fatty acids.

Abstract: Disclosed are transaminase mutants and use thereof. The amino acid sequence of the transaminase mutant is obtained by the mutation of the amino acid sequence as shown in SEQ ID NO: 1, and the mutation at least comprises one of the following mutation sites: the 19-th site, the 41-th site, the 43-th site, the 72-th site, the 76-th site, the 92-th site, the 107-th site, the 125-th site, the 132-th site, the 226-th site, the 292-th site, the 295-th site, the 308-th site, and the 332-th site; and the 19-th site is mutated into a serine, the 41-th site is mutated into a serine, the 43-th site is mutated into an asparagine, a glycine in the 72-th site is mutated into a leucine, etc.; or the amino acid sequence of the transaminase mutant has the mutation sites in the mutanted amino acid sequence, and has more than 80% homology to the mutanted amino acid sequence.

Abstract: The invention provides a transaminase mutant and application thereof, wherein the amino acid sequence of the transaminase mutant is formed after mutation of the amino acid sequence as shown in SEQ ID NO: 1, and mutated amino acid sites comprise T7C+S47C sites. The transaminase mutant having the mutation sites can be further prepared into an immobilized enzyme through an immobilization technology, the immobilized enzyme has relatively high activity and high stability, can be recycled for multiple times, and is applicable to continuous flow reaction in a packed bed.

Abstract: The present invention provides a microorganism-derived soluble coenzyme-binding glucose dehydrogenase which catalyzes a reaction for oxidizing glucose in the presence of an electron acceptor, has an activity to maltose as low as 5% or less, and is inhibited by 1,10-phenanthroline. The invention also provides a method for producing the coenzyme-binding glucose dehydrogenase, and a method and a reagent for measuring employing the coenzyme-binding glucose dehydrogenase. According to the invention, the coenzyme-binding glucose dehydrogenase can be applied to an industrial field, and a use becomes possible also in a material production or analysis including a method for measuring or eliminating glucose in a sample using the coenzyme-binding glucose dehydrogenase as well as a method for producing an organic compound. It became also possible to provide a glucose sensor capable of accurately measuring a blood sugar level.

Abstract: The present invention has an object of providing a modified lipase having excellent stability and reactivity at a high temperature. Provided is a modified lipase with improved reactivity and/or stability at a high temperature, the modified lipase having an amino acid sequence including one or more amino acid substitutions which are selected from the group consisting of T130C-S153C, A249P, F259Y, S282P, S283Y and S300P in the amino acid sequence represented by SEQ ID NO: 1, or an amino acid sequence having 90% or more sequence identity therewith.

Abstract: The technology relates in part to methods and compositions for isothermal amplification of nucleic acids.

Abstract: A construct composed of a Kinesin-derived Angiogenesis Inhibitor peptide and one or more carrier moieties and/or stabilizing moieties is provided as are methods for inhibiting angiogenesis and treating a disease or condition characterized by excessive vascularity.

Abstract: Compositions and methods comprising polynucleotides and polypeptides having glyphosate-N-acetyltransferase (GLYAT) activity are provided. In specific embodiments, the sequence has an improved property, such as, but not limited to, an improved specificity for glyphosate when compared to an appropriate control resulting in decreased off target acetylation of, e.g. an amino acid such as aspartate. Further provided are nucleic acid constructs, plants, plant cells, explants, seeds and grain having the GLYAT sequences. Various methods of employing the GLYAT sequences are provided. Such methods include methods for producing a glyphosate tolerant plant, plant cell, explant or seed and methods of controlling weeds in a field containing a crop employing the plants and/or seeds disclosed herein.

Abstract: Provision of a mutant ?-glucosidase having high protease resistance. A mutant ?-glucosidase consists of an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1, wherein the amino acid sequence comprises Gln and Thr respectively at positions corresponding to positions 649 and 655 of SEQ ID NO: 1 or Tyr-Glu-Pro-Ala-Ser-Gly in a region corresponding to the region from position 653 to position 658 of SEQ ID NO: 1, and has ?-glucosidase activity.

Abstract: The present invention is directed to antimicrobial agents and compositions including the same. The antimicrobial agent can include a polypeptide or a peptidomimetic of the polypeptide. The polypeptide can have a net positive charge of at least about 3 at a pH of 7.0, and a hydrophobicity of greater than 25%.

Abstract: Provided is a method for measuring tyrosine phosphatase and tyrosine kinase activity, as a high-sensitivity measuring method, which is suitable for high throughput and which uses a compound represented by general formula (I) (in the formula, A represents a conjugated ring; L represents a linker or the like having a labeling substance at an end; R1 represents a hydrogen atom or the like; and R2 and R3 each represent a hydrogen atom, an alkyl group or the like).

Abstract: The present disclosure provides engineered transaminase polypeptides useful for the synthesis of chiral amine compounds under industrially relevant conditions. The disclosure also provides polynucleotides encoding the engineered transaminase polypeptides, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases for the production of chiral amine compounds.

Abstract: Provided herein are new compositions and methods to target and deliver agents to pathological areas by utilizing multifunctional compounds. These compounds include three or more domains: (i) a vimentin-binding peptide, (ii) a linker, and (iii) a drug binding, a capturing reagent, or a detectable moiety. These compounds can be used to detect, isolate, and/or treat cancerous cells such as circulating tumor cells.

Abstract: The present invention relates to antibodies that bind blood brain barrier receptors (BBB-R) and methods of using the same.

Abstract: A method includes combining a polynucleotide and an amplification reagent mixture to form a reaction mixture, wherein the reaction mixture comprises reversibly bound divalent ions in solution, and adjusting the pH of the reaction mixture to release the reversibly bound divalent ions, thereby initiating amplification of the polynucleotide.

Abstract: Provided is GDH with increased applicability to glucose sensors. A composition contains FADGDH, wherein when 0.1 mL of the composition is added to 2.9 mL of a solution containing 10 mM of trehalose and 1 mmol/L of potassium ferricyanide to give a glucose dehydrogenase activity of 500 U/mL and incubated at 37° C., the decrease in absorbance at 405 nm resulting from reduction of the potassium ferricyanide is less than 20 mAbs per minute.

Abstract: The present disclosure provides engineered RNA-guided enzymes for editing live cells.

Abstract: The present invention relates to preparation and application of a cyclodextrin glucosyltransferase mutant, belonging to the fields of gene engineering and enzyme engineering. By mutating amino acids of cyclodextrin glucosyltransferase, the enzyme activity of the obtained mutant can reach 2.5 times that of wild enzyme. In addition, the cyclodextrin glucosyltransferase mutant obtained in the present invention is simple in purification and suitable for industrial production.

Abstract: The invention includes a tetrapeptide to be used in the treatment of Alzheimer's disease and depression. The tetrapeptide comprises the general formula, acetyl-X-ARG-ARG-amide, where X=-(D-ARG)-ARG-; -(D-LYS)-LYS-; or -(D-MET)-MET-. On the basis of the combination of pharmacological properties identified, a preparation including the tetrapeptide has potential for clinical use as a nootropic, neuroprotective, and antidepressant agent.

Abstract: Angiotensin (1-7) analogs are provided. Also provided are methods of making such analogs methods for using analogs as therapeutic compositions such as, for example, treatment cancer.

Abstract: A method of producing a long-chain fatty alcohol, containing culturing a microorganism wherein expression of a gene encoding a 3-ketoacyl-ACP synthase and expression of a gene encoding a fatty acyl-CoA reductase are enhanced; a method of providing ability to produce a long-chain fatty alcohol for a microorganism wherein expression of a gene encoding a 3-ketoacyl-ACP synthase and expression of a gene encoding a fatty acyl-CoA reductase are enhanced in a microorganism cell; and a transformant of a microorganism in which expression of a gene encoding a ?-ketoacyl-ACP synthase and expression of a gene encoding a fatty acyl-CoA reductase are enhanced.

Abstract: Disclosed are methods for polynucleotide sequencing that detect the location of selected nucleobases with greater precision. The methods can be used to determine the location and nature of modified bases in a polynucleotide, that is, non-canonical bases, or to improve accuracy of sequencing of “problem” regions of DNA sequencing such as homopolymers, GC rich areas, etc. The sequencing method exemplified is nanopore sequencing. Nanopore sequencing is used to generate a unique signal at a point in a polynucleotide sequence where an abasic site (AP site, or apurinic or apyrimidinic site) exists. As part of the method, an abasic site is specifically created enzymatically using a DNA glycosylase that recognizes a pre-determined nucleobase species and cleaves the N-glycosidic bond to release only that base, leaving an AP site in its place.

Abstract: Methods for treating angiogenesis-mediated diseases are disclosed. More particularly, the present disclosure relates to methods of inhibiting ferrochelatase as an antiangiogenic therapy.

Abstract: The present invention relates to nucleic acid molecules containing poly (dA:dT) regions which are stabilized in E. coli, methods of propagating such nucleic acid molecules in E. coli, methods of obtaining RNA, peptides or proteins using such nucleic acid molecules and to RNA which is obtained from such nucleic acid molecules and its use. In particular, the poly (dA:dT) regions contain at least one disruption by a sequence not encoding a sequence solely composed of A residues.

Abstract: A method is provided for modifying yeast to express mutant avian farnesyl disphospate synthase and the resulting modified yeast. The yeast advantageously includes additional mutants including but not limited to having ergosterol dependent growth and being erg-. The modified yeast are beneficial for the production of various terpenes including diterpenes.

Abstract: Herein provided are peptide inhibitors and methods for treating polyglutamine (polyQ) diseases. Also disclosed are related compositions and kits for therapeutic use in the treatment of polyQ diseases.

Abstract: Disclosed herein are synthetic peptides and compositions comprising the same for the treatment and/or prophylaxis of a disease or a condition related to dry eye syndrome, psoriasis vulgaris or multiple myeloma. Also disclosed herein are methods of treating and/or preventing a disease or a condition related to dry eye syndrome, psoriasis vulgaris or multiple myeloma, by administering to a subject in need of such treatment a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.

Abstract: Provided are a novel separated polypeptide having transaminase activity, a polynucleotide encoding the polypeptide, a microorganism including the polynucleotide, and a method of deaminating an amino compound by using the polypeptide or the microorganism.

Abstract: A method for perming or coloring hair, in which hair is treated with a cosmetic composition including a protein-glutaminase and not including an alkaline substance. A method of enhancing hair-permeation of an active ingredient included in a cosmetic composition, in which a protein glutaminase is included in the cosmetic composition. The cosmetic composition does not include an alkaline substance, and the active ingredient is at least one of a hair perm agent and a hair coloring agent.

Abstract: The present invention relates to a transformed mammalian cell including a heterologous nucleic acid sequence (i) encoding a polypeptide including the catalytic domain of ST6Gal1 or of ST6Gal2 and, optionally, at least one nucleic acid sequence (ii) encoding a therapeutic protein including at least one glycosylation site, the transformed mammalian cell expressing the therapeutic protein with a sialylation on the at least one glycosylation site.

Abstract: The present invention addresses a problem of providing a lipase derived from a microorganism that is specific for short-chain to medium-chain fatty acids. A modified lipase is obtained by making a substitution in the amino acid sequence of a Candida cylindracea derived lipase, wherein the substitution is (1) a substitution of asparagine for an amino acid corresponding to the amino acid at position 428 in the amino acid sequence set forth in SEQ ID NO: 1; or (2) a substitution of phenylalanine, methionine, or isoleucine for an amino acid corresponding to the amino acid at position 429 in the amino acid sequence set forth in SEQ ID NO: 1.

Abstract: The invention provides compositions and methods for engineering bacteria to produce sialylated and N-acetylglucosamine-containing oligosaccharides, and the use thereof in the prevention or treatment of infection.

Abstract: High molecular weight heparosan polymers are described, as are methods of producing and using the high molecular weight heparosan polymers.

Abstract: Compositions and methods comprising polynucleotides and polypeptides having glyphosate-N-acetyltransferase (GLYAT) activity are provided. In specific embodiments, the sequence has an improved property, such as, but not limited to, an improved specificity for glyphosate when compared to an appropriate control resulting in decreased off target acetylation of, e.g. an amino acid such as aspartate. Further provided are nucleic acid constructs, plants, plant cells, explants, seeds and grain having the GLYAT sequences. Various methods of employing the GLYAT sequences are provided. Such methods include methods for producing a glyphosate tolerant plant, plant cell, explant or seed and methods of controlling weeds in a field containing a crop employing the plants and/or seeds disclosed herein.

Abstract: As described herein, an peptide of SEQ ID NO: 1 is modified at the terminal end. Specifically, the carboxyl-group of the leucine at the terminal end of the amino acid sequence FCIGRL (SEQ ID NO: 1) is modified with a —CONH2. This modified peptide is used as a permeation enhancer to boost the mucous membrane permeation, thereby noticeably increasing the bioavailability of a drug that is administered together with the modified peptide. The drug to be administered with the modified peptide can be cyclosporine A.

Abstract: Provided is a cyanobacterium improved in fatty acid productivity. A method for producing a modified cyanobacterium, comprising causing loss of function of a LexA transcriptional regulator and acyl-ACP synthetase in a cyanobacterium.

Abstract: A group of LIMP-2 peptides, LIMP-2 polypeptides, variants thereof, and pharmaceutical compositions comprising the LIMP-2 peptides, LIMP-2 polypeptides, or variants thereof are described. The disclosed peptides and polypeptides preferably comprise an amino acid sequence that is sufficient for providing a biological activity associated with LIMP-2, which may include binding and/or activating biological molecules such as ?-glucocerebrosidase and binding viral protein 1 (VP1) of enterovirus 71 (E71) or coxsackievirus A16 (CA16). Also disclosed are methods of using the LIMP-2 peptides, LIMP-2 polypeptides, and variants thereof as therapeutics for treating diseases and disorders associated with ?-glucocerebrosidase activity in subjects in need thereof.

Abstract: The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.

Abstract: Glutamine phenylpyruvate transaminase (GPT) proteins, nucleic acid molecules encoding GPT proteins, and uses thereof are disclosed. Provided herein are various GPT proteins and GPT gene coding sequences isolated from a number of plant species. As disclosed herein, GPT proteins share remarkable structural similarity within plant species, and are active in catalyzing the synthesis of 2-hydroxy-5-oxoproline (2-oxoglutaramate), a powerful signal metabolite which regulates the function of a large number of genes involved in the photosynthesis apparatus, carbon fixation and nitrogen metabolism.

Abstract: The present invention generally relates to non-aqueous solutions of plant growth regulator(s) and polar and/or semi-polar organic solvent(s), methods for making said non-aqueous solution, and methods for improving the growth and crop productivity of plants using said non-aqueous solution.